Research Advances of PD-1/PD-L1 Inhibitors Combined with Angiogenesis Inhibitors in Treatment of Advanced Triple-negative Breast Cancer

Advanced triple-negative breast cancer(TNBC) has less treatments, shorter survival time and poorer prognosis than other subtypes of breast cancer. The rapid development of immunotherapy in recent years is expected to prolong the survival time of advanced TNBC patients, but multiple clinical studies have suggested that PD-1/PD-L1 inhibitor monotherapy have a low efficiency in the treatment of advanced TNBC. Recent studies have shown that the treatment with angiogenesis inhibitors can not only normalize blood vessels and inhibit tumor growth, but also enhance the efficacy of immunotherapy. Angiogenesis inhibitors combined with PD-1/PD-L1 inhibitors have synergistic effects. This article analyzes the mechanism of PD-1/PD-L1 inhibitors and angiogenesis inhibitors, reviews the preclinical and clinical studies on the combination of two types of drugs in the treatment of advanced TNBC and summarizes their efficacy and safety, to provide new perspectives and ideas for the treatment strategy of advanced TNBC.